ANI Pharmaceuticals, Inc.
ANIP
$67.36
$0.110.16%
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -0.13% | 13.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.13% | 13.11% | |||
| Cost of Revenue | 11.06% | 13.76% | |||
| Gross Profit | -6.56% | 12.75% | |||
| SG&A Expenses | 5.84% | 8.38% | |||
| Depreciation & Amortization | -0.09% | 3.52% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.59% | 12.93% | |||
| Operating Income | -43.41% | 14.54% | |||
| Income Before Tax | -91.77% | 119.30% | |||
| Income Tax Expenses | -113.24% | 257.73% | |||
| Earnings from Continuing Operations | -88.38% | 59.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -88.38% | 59.17% | |||
| EBIT | -43.41% | 14.54% | |||
| EBITDA | -21.88% | 8.78% | |||
| EPS Basic | -91.96% | 54.21% | |||
| Normalized Basic EPS | -34.18% | 33.45% | |||
| EPS Diluted | -91.93% | 56.00% | |||
| Normalized Diluted EPS | -34.10% | 33.05% | |||
| Average Basic Shares Outstanding | 0.64% | 6.76% | |||
| Average Diluted Shares Outstanding | 0.49% | 7.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 7.61% | -0.37% | |||
